E. Small

Publications781
h-index101
Citations52,538
Highly Influential Citations1,684
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Scher
  • 1,131 Publications • 102,665 Citations
  • J. D. de Bono
  • 785 Publications • 64,721 Citations
  • P. Kantoff
  • 906 Publications • 71,893 Citations
  • K. Fizazi
  • 990 Publications • 51,163 Citations
  • Publications
  • Influence
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
TLDR
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
TLDR
The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
TLDR
New consensus criteria for eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone are defined, with increasing emphasis on time-to-event end points as decision aids in proceeding from phase II to phase III trials.
Abiraterone in metastatic prostate cancer without previous chemotherapy.
TLDR
Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
TLDR
It is suggested that sipuleucel-T may provide a survival advantage to asymptomatic HRPC patients in a phase III study and was well tolerated.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced…
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
TLDR
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
TLDR
Patients who developed HTN on bevacizumab plus IFN-alpha had a significantly improved PFS and OS versus patients without HTN, and HTN may be a biomarker of outcome with bevaccizumAB plus IFn-alpha.
Prostate Cancer, Version 1.2016.
TLDR
This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
TLDR
The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.
...
1
2
3
4
5
...